Combined autophagy and proteasome inhibition
Dan T. Vogl, Edward Allen Stadtmauer, Kay-See Tan et al. · Autophagy · 2014
The efficacy of proteasome inhibition for myeloma is limited by therapeutic resistance, which may be mediated by activation of the autophagy pathway as an alternative mechanism of protein degradation. Preclinical studies demonstrate that autophagy inhibition with hydroxychloroquine augments the antimyeloma efficacy of the proteasome inhibitor bortezomib. We conducted a phase I trial combining bortezomib and hydroxychloroquine for relapsed or refractory myeloma. We enrolled 25 patients, including 11 (44%) refractory to prior bortezomib. No protocol-defined dose-limiting toxicities occurred, and we identified a recommended phase 2 dose of hydroxychloroquine 600 mg twice daily with standard doses of bortezomib, at which we observed dose-related gastrointestinal toxicity and cytopenias. Of 22 patients evaluable for response, 3 (14%) had very good partial responses, 3 (14%) had minor responses, and 10 (45%) had a period of stable disease. Electron micrographs of bone marrow plasma cells collected at baseline, after a hydroxychloroquine run-in, and after combined therapy showed therapy-associated increases in autophagic vacuoles, consistent with the combined effects of increased trafficking of misfolded proteins to autophagic vacuoles and inhibition of their degradative capacity. Combined targeting of proteasomal and autophagic protein degradation using bortezomib and hydroxychloroquine is therefore feasible and a potentially useful strategy for improving outcomes in myeloma therapy.
Cited by 368 works. doi:10.4161/auto.29264 Open-access PDF
Authors
- Dan T. Vogl
- Edward Allen Stadtmauer
- Kay-See Tan
- Daniel F. Heitjan
- Lisa E. Davis
- Laura Pontiggia
- Reshma A. Rangwala
- Shengfu Piao
- Yunyoung Claire Chang
- Emma Catherine Scott
- Charles W. Nichols
- David Porter
- Janeen Kaplan
- Gayle Mallon
- James E. Bradner
- Ravi K. Amaravadi
References
- International uniform response criteria for multiple myeloma
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
- Autophagy in Health and Disease: A Double-Edged Sword
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- Autophagy in cell death: an innocent convict?
- Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages.
- Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma
- Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma
- Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
- HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS